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Abstract: Drug budget and prescription control measures are implemented regionally in Germany,
meaning that the uptake of pharmaceuticals, including biosimilars, can vary by region. We examine
regional market dynamics of tumor necrosis factor alpha (TNFα) inhibitor originators and biosimilars
in Germany and studied the influence of biosimilar policies on these dynamics. This study is based on:
(1) a literature review in which German biosimilar policies are identified, (2) the analysis of dispensing
data (2010–2018) for the class of TNFα inhibitors, and (3) ten semi-structured interviews investigating
prescribers’ and insurers’ views on factors potentially influencing biosimilar uptake. The analysis of
biosimilar market shares of infliximab and etanercept revealed wide variations across the 17 German
Regional Associations of Statutory Health Insurance Accredited Physicians (PA regions). Quantitative
analyses indicated that biosimilar market shares for infliximab and etanercept were significantly
lower in former East Germany when compared to former West Germany regions. Through qualitative
interview analyses, this study showed that the use of infliximab and etanercept biosimilars across
Germany is primarily influenced by (1) the regional-level implementation of biosimilar quotas and
the presence of monitoring/sanctioning mechanisms to ensure adherence to these quotas, (2) the
different insurer-manufacturer discount contracts, and (3) gainsharing arrangements established at
the insurer-prescriber level.
Keywords: infliximab; etanercept; TNFα inhibitors; biologics; biosimilars; Germany; policies;
incentives; uptake; market dynamics
1. Introduction
The incorporation of biologic therapies into clinical practice has positively transformed health
outcomes for many patients diagnosed with severe and highly debilitating chronic conditions [1–3].
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As a result, these therapies have represented a growing market in recent decades (accumulated global
sales of USD 312 billion in 2018) [4]. Being approved for an increasing number of disease areas,
high-cost biologic therapies constitute an important budget impact to be managed by healthcare
systems across Europe [5]. However, with the expiration of patents and other exclusivity rights for
biologics, non-innovator and therapeutically equivalent versions, i.e., biosimilars, enter the market
with the potential to create competition within the therapeutic classes [6]. This leads to altered market
dynamics and potentially to decreasing treatment costs and increasing patient access to biologic
therapies [7].
Germany, with 83 million inhabitants [8], is the most populous country of the European Union and
is an important market for biologics and biosimilars [9,10]. Here, sales of biologics amounted to EUR 11
billion in 2017 [11]. An important class of biologics that has been subject to competition by biosimilars
is that of TNFα inhibitors (sales of EUR 2.2 billion in 2017 for Germany) [4]. Five active substances
with a TNFα neutralizing activity (infliximab, etanercept, adalimumab, golimumab and certolizumab
pegol) are available for the treatment of immune-mediated inflammatory diseases [12]. The originator
products—Remicade® (infliximab), Enbrel® (etanercept) and Humira® (adalimumab)—have been
present in the German pharmaceuticals market for more than 15 years now. In 2013, infliximab
biosimilars under the names Inflectra® and Remsima® received marketing authorization by the
European Medicines Agency (EMA) and accessed different European markets. Consequently, in
2015, Inflectra® and Remsima® were launched in Germany. They were followed by the market entry
of infliximab biosimilars Flixabi® (2016) and Zessly® (2018). In the case of etanercept, biosimilar
products Benepali® and Erelzi® were brought to the German market in 2016 and 2017, respectively [11].
The offer of TNFα inhibitors has been expanded with the incorporation of adalimumab biosimilars
Imraldi®, Hyrimoz®, Amgevita®, Hulio® in the last quarter of 2018 and the posterior market launch
of Idacio ® (2019) and awaits further developments, once exclusivity rights for Cimzia® (certolizumab
pegol) and Simponi® (golimumab) have expired in 2021 and 2024, respectively [13,14].
The German law for more safety in the supply of pharmaceuticals (German: Gesetz für mehr
Sicherheit in der Arzneimittelversorgung, GSAV June 2019) has been recently amended to optimize the
use of biosimilar products as a cost-containment tool [15]. The introduced changes would provide
a more favorable environment for the close monitoring of biosimilar regional market dynamics
at the federal level. This is of relevance based on the decentralized organization of the German
healthcare system, where the German regions are responsible for managing prescription and drug
budget control activities. Regional differences in biosimilar policies and practices have been associated
with the heterogeneous uptake of biosimilars between product classes and across regions [15–18].
In Germany, differences in biosimilar market shares were described for TNFα inhibitors at the end
of 2018: in Westphalia-Lippe and Lower Saxony, biosimilar uptake was two times higher than in
Baden-Württemberg. However, reasons behind the variable uptake of biosimilars across the 17 German
Regional Associations of Statutory Health Insurance Accredited Physicians (PA regions; German:
Kassenärztliche Vereinigungen (KV)) have not been examined in detail [19].
In this study, we analyze the regional market dynamics of TNFα inhibitors following the entry of
biosimilars for infliximab and etanercept, and investigate the influence of diverse factors, especially
biosimilar policies and practices, on biosimilar uptake. This study builds on previous research analyzing
regional market dynamics of infliximab and etanercept originators and biosimilars in Sweden (see
Box 1) [17,18].
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Box 1. Summary of what is already known about this topic and the added value of the study.
What is already known about this topic
- Regional variations in the use of TNFα inhibitor biosimilars in Sweden have been attributed to the
extent of actual (discounted/rebated) price differences between biosimilars and the originator product, the
engagement of key opinion leaders, the issuance of local guidelines and to gainsharing arrangements [17,18].
- In Germany, biosimilar uptake is also known to vary at the regional level. This was investigated by
Blankart et al. for erythropoiesis-stimulating substances, filgrastim and somatropin. Variations in biosimilar
uptake were partly attributed to the presence of explicit regional cost-control measures, such as quota
regulations [54].
What this study adds
- Although previous studies have characterized regional variations in the uptake of TNFα inhibitor biosimilars
in Germany, the reasons behind this variable uptake have not been examined in detail [19].
- This study highlights the influence of prescription and budget control activities (organized at the regional
and insurer level) on the variable uptake of infliximab and etanercept biosimilars.
2. Results
2.1. Overview of TNFα Inhibitor Dynamics in the German Healthcare System
2.1.1. The German Market for TNFα Inhibitors
In Germany, the federal and regional governments delegate certain healthcare responsibilities
to self-regulated organizations of payers and providers that can operate within the Statutory Health
Insurance (SHI; German: Gesetzliche Krankenversicherung (GKV)) scheme or the substitutive Private
Health Insurance (PHI; German: Private Krankenversicherung (PKV)) scheme. Within SHI, the main
payers are multiple membership-based not-for-profit insurance companies (sickness funds; German:
Krankenkassen), which may function nationwide or at the regional level [20]. According to SHI data,
originator products Humira®, Enbrel® and Simponi® and a biosimilar version of Enbrel® (Benepali®)
still ranked in 2018 among the top 30 contributors to pharmaceutical expenditure [19]. Due to the
scheme for care delivery in Germany, most of this expenditure is managed by the ambulatory sector,
through which the majority of prescriptions for TNFα inhibitors are issued. In Germany, there is a clear
distinction in the provision of outpatient and hospital care. Outpatient care is delivered by individual
doctor practices and specialized medical centers, where services are provided that are usually a
hospital competence across Europe [21,22]. In this sense, most prescriptions for intravenous infliximab
(70% issued by gastroenterologists) and subcutaneous etanercept (87% issued by rheumatologists)
go through the German ambulatory sector [11]. Within this sector, sickness funds negotiate overall
prescription budgets with the Federal Association of Statutory Health Insurance Physicians (German:
Kassenärztliche Bundesvereinigung (KBV)). They also contract prescription budgets for the regions
through negotiations with the 17 German PA regions. Although Germany is divided into 16 federal
states (German: Bundesländer), the areas Northrhine and Westphalia-Lippe within the state of
Northrhine-Westphalia are represented by two independent PA regions [19].
2.1.2. Regulations of the German Market for TNFα Inhibitors
TNFα inhibitor therapies entered the German market under a free-pricing and full reimbursement
scheme (up to a patient co-payment of at most EUR 10 per pack dispensed). However, lower list prices
are expected for biosimilars when compared to the originator. While price setting for pharmaceuticals in
the hospital market is unregulated and established through direct hospital-manufacturer negotiations,
some instruments for regulation are applicable to the retail market [19]. For example, reference price
groups were established for infliximab and etanercept in accordance with §35 German Social Code
Book V (German: Sozialgesetzbuch V (SGB V)) [23]; the reference price acts as a reimbursement limit,
with any overshooting cost borne by the patient. The inclusion of all infliximab-containing products
into a reference price group resulted in a 22% reduction in Remicade®’s selling price at the end of
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2018 [19]. Until recently, the German Legislation (§129 SBG V) only allowed automatic substitution for
bioidenticals (i.e., biosimilars made by the same production site and process, as is the case for Inflectra®
and Remsima®) [19]. Modifications of the law for more safety in the supply of pharmaceuticals
(GSAV) have extended these regulations to non-bioidentical biosimilars, provided that the Federal
Joint Committee (German: Gemeinsamer Bundesausschuss (G-BA)) recognizes interchangeability [15].
Based on the restrictions for automatic substitution of biologics, the type of procurement contract
(§130a SGB V) usually applied to generics has been deemed inadequate for biosimilars. Despite the
various alternative procurement mechanisms possible (e.g., tendering), insurance companies mostly
rely on the organization of “open-house rebate contracts” (German: Open-House-Rabattverträge) in
which all suppliers of originator biologics and biosimilars can participate. Participants in “open-house
rebate contracts” qualify to sign a supply contract if they adhere to certain pre-defined contractual
conditions, including mandatory discounts on list prices. These conditions are freely set by the insurer
and cannot depend on individual negotiations with certain suppliers [19].
The market for TNFα inhibitors is indirectly regulated through the establishment of prescribing
targets. Every year, the National Association of Statutory Health Insurance Funds (German: Gesetzliche
Krankenversicherung-Spitzenverband (GKV-SV) and KBV agree on target areas for prescribing
control (biosimilars included). For these areas, they use the previous year’s prescription rates
to set recommendations. The output of this negotiation is reflected in a non-binding contract
(German: Bundesrahmenvorgaben für die Arzneimittelvereinbarungen) that serves as a guideline
for regional agreements. Insurer companies and regional physician associations look at the national
advisory agreement and define implementation details for contracts which are binding at the regional
level (German: Arzneimittelvereinbarungen). Minor deviations are allowed, as long as the overall
cost-containment effect is achieved. This means that regional physician associations are not forced
to rely on biosimilar prescription quotas. Instead, they can give more importance to alternative
cost-containment mechanisms that still meet the general objective [19].
2.2. Analysis of Dispensing Data for TNFα Inhibitors
2.2.1. TNFα Inhibitor Products: Evolution in Sales Volume
Overall, in Germany, the sales volume of TNFα inhibitor products has increased over time (from
17.68M defined daily doses (DDDs) in 2010 to 42.06M DDDs in 2018). From 2010 to 2018, sales volume
for infliximab and adalimumab increased over two-fold, and 1.8-fold for etanercept (see Figure 1).
The rise in the sales volume of TNFα inhibitors has been attributed to several factors (e.g., the lower
threshold at which treatment with biologics is initiated, changes in the dosing regimen) [24,25]. In
the case of infliximab and etanercept, the data in this study showed that year-over-year increases
(%) in use occurred shortly after biosimilar entry (13.4% increase for infliximab and 13.7% increase
for etanercept).
The compound annual growth rate (CAGR) of sales volume (DDDs) indicated different growth
trends for infliximab and etanercept (see Figure 1). While growth intensified for etanercept in the
last few years, it decreased in the case of infliximab. This suggests a saturation of the market for
infliximab, which has been subject to the competitive pressure of TNFα inhibitor therapies with a
different administration profile and approval for an extended range of indications [7].
Figure 2 shows the composition of the market for TNFα inhibitors in terms of individual products
from 2010 until 2018. In 2010, the greatest volume share corresponded to adalimumab (40%), while
the shares for infliximab and etanercept were 21% and 34%, respectively. The volume share for the
innovative products Cimzia® and Simponi® amounted to 5%. During a nine-year time period, the
volume share for adalimumab remained stable, while the shares for infliximab and etanercept decreased
in favor of the originator therapies Cimzia® and Simponi®. The data represented in Figure 2 indicate
that the market entry of infliximab biosimilars (2015) has not induced a shift in prescribing trends
from other TNFα inhibitor originator products (Enbrel®, Humira®, Cimzia®, Simponi®) towards
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infliximab-containing products. This observation also applies to the entry of etanercept biosimilars
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2.2.2. Infliximab and Etanercept Biosimilars and Originators: Evolution in Market Shares for the
German Regions
At the end of 2018, the combination of biosimilar products for infliximab and etanercept represented,
in terms of sales volume (DDDs), 25% of the German market for TNFα inhibitors (see Figure 3).
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Figure 3. Composition of the market for TNF α inhibitors in terms of biosimilar products (2015–2018).
Biosimilar market shares (%) for infliximab and etanercept are calculated in relation to the total volume
of TNFα inhibitors.
The level of biosimilar penetration for infliximab and etanercept was comparable (56% and 61%,
respectively) in Germany at the end of the third year after biosimilar market entry (see Figure 4).
However, regional data on the uptake of infliximab and etanercept biosimilars (Q4 2018) pointed to a
wide variation in biosimilar market shares between the 17 German PA regions (see Table 1). In the case
of infliximab, the lowest biosimilar market share was observed for Brandenburg (33%), while the largest
value was observed for Lower Saxony (87%). In a similar way, there was large variance of market
shares for etanercept, with Brandenburg being the region with the lowest biosimilar uptake (33%)
and Westphalia-Lippe being the highest (77%). The time evolution analysis of market shares showed
that in general, regions with an early adoption of biosimilars (e.g., Northrhine, Westphalia-Lippe)
also reached high biosimilar uptake levels (Q4 2018). Exceptions to this trend were identified (e.g.,
Brandenburg). While Brandenburg behaved as an early adopter of infliximab biosimilars, uptake
levels at the end of 2018 were low.
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Table 1. Market shares (%) of biosimilar infliximab and etanercept in Germany’s 17 PA regions. Colors gradually change from red to green with increasing biosimilar
market shares.
Q1
2015
Q2
2015
Q3
2015
Q4
2015
Q1
2016
Q2
2016
Q3
2016
Q4
2016
Q1
2017
Q2
2017
Q3
2017
Q4
2017
Q1
2018
Q2
2018
Q3
2018
Q4
2018
INFLIXIMAB
Lower Saxony 2% 11% 17% 24% 26% 34% 40% 48% 74% 76% 83% 84% 88% 88% 87% 87%
Westphalia-Lippe 3% 20% 25% 33% 40% 49% 57% 64% 68% 73% 77% 79% 83% 84% 86% 86%
Bavaria 2% 12% 18% 25% 30% 37% 38% 42% 55% 66% 70% 72% 75% 77% 78% 78%
Bremen 0% 3% 14% 21% 24% 10% 22% 38% 37% 48% 53% 58% 61% 71% 74% 77%
Schleswig Holstein 2% 9% 12% 13% 20% 21% 25% 27% 33% 40% 38% 47% 55% 63% 73% 76%
Rhineland Palatinate 1% 11% 17% 25% 25% 37% 41% 47% 55% 59% 60% 69% 69% 70% 62% 70%
Northrhine 1% 13% 27% 32% 40% 46% 50% 53% 57% 57% 61% 62% 63% 67% 69% 70%
Saarland 3% 24% 22% 24% 31% 33% 44% 49% 61% 57% 61% 63% 65% 67% 67% 69%
Hesse 6% 19% 28% 38% 44% 42% 43% 45% 47% 52% 51% 55% 55% 56% 58% 60%
Mecklenburg Western Pomerania 0% 0% 7% 8% 11% 12% 12% 25% 22% 28% 46% 43% 42% 43% 48% 58%
Thuringia 1% 3% 8% 15% 22% 26% 24% 23% 27% 36% 39% 50% 54% 56% 59% 53%
Hamburg 0% 1% 6% 11% 17% 14% 16% 21% 22% 25% 31% 34% 39% 43% 49% 52%
Baden-Württemberg 1% 3% 8% 12% 14% 14% 16% 21% 27% 30% 34% 41% 42% 48% 47% 49%
Berlin 0% 2% 5% 10% 15% 26% 29% 31% 36% 36% 38% 40% 43% 45% 44% 49%
Saxony-Anhalt 8% 29% 35% 31% 27% 27% 27% 25% 31% 42% 43% 46% 51% 53% 53% 48%
Saxony 0% 3% 4% 9% 10% 14% 14% 16% 18% 20% 22% 29% 33% 36% 40% 45%
Brandenburg 7% 21% 25% 25% 27% 30% 29% 31% 30% 29% 28% 29% 30% 33% 34% 33%
ETANERCEPT
Westphalia-Lippe 0% 0% 0% 0% 0% 22% 38% 47% 55% 59% 62% 66% 71% 75% 76% 77%
Lower Saxony 0% 0% 0% 0% 0% 3% 9% 25% 48% 55% 61% 65% 69% 70% 73% 74%
Bavaria 0% 0% 0% 0% 0% 4% 10% 17% 34% 46% 50% 55% 61% 63% 65% 68%
Northrhine 0% 0% 0% 0% 0% 8% 14% 20% 28% 33% 39% 47% 54% 59% 63% 67%
Hamburg 0% 0% 0% 0% 0% 1% 5% 11% 17% 21% 22% 27% 40% 49% 57% 62%
Schleswig Holstein 0% 0% 0% 0% 0% 4% 7% 11% 17% 22% 28% 31% 44% 53% 57% 60%
Rhineland Palatinate 0% 0% 0% 0% 0% 5% 11% 19% 30% 35% 40% 46% 51% 53% 56% 59%
Bremen 0% 0% 0% 0% 0% 3% 8% 18% 28% 29% 37% 39% 47% 47% 54% 55%
Hesse 0% 0% 0% 0% 0% 4% 13% 15% 19% 22% 24% 28% 32% 35% 41% 50%
Saxony-Anhalt 0% 0% 0% 0% 0% 2% 5% 7% 11% 16% 21% 28% 39% 44% 43% 46%
Baden-Württemberg 0% 0% 0% 0% 0% 4% 11% 16% 23% 26% 30% 32% 37% 38% 42% 46%
Saarland 0% 0% 0% 0% 0% 4% 8% 10% 18% 19% 19% 25% 26% 34% 34% 42%
Saxony 0% 0% 0% 0% 0% 1% 3% 6% 9% 13% 17% 24% 31% 37% 39% 40%
Berlin 0% 0% 0% 0% 0% 2% 6% 11% 16% 19% 22% 26% 28% 32% 35% 37%
Mecklenburg Western Pomerania 0% 0% 0% 0% 0% 2% 4% 8% 13% 16% 18% 21% 26% 30% 36% 37%
Thuringia 0% 0% 0% 0% 0% 1% 2% 4% 5% 9% 11% 17% 23% 25% 33% 35%
Brandenburg 0% 0% 0% 0% 0% 3% 6% 10% 12% 14% 16% 19% 24% 25% 31% 33%
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Figure 4. Biosimilar pen tra ion for infliximab and etanercept in Germany over time. Biosimilar market
shares (%) calcul t d s volume of biosimilars over volume of biosi ilars plus the originator
product (DDDs).
Biosimilar uptake patterns f r infliximab and et nercept w e similar across Germany in Q4 2018
(see Figure 5). Indeed, regional biosimila market share for infl ximab and etanercept were positively
correlated (adjusted R2 = 0.64). This allowed us to identify common low- and high-biosimilar uptake
regions. Saxony, Saxony-Anhalt, Brandenburg, Berlin and Baden-Württemberg showed low uptake for
both infliximab and etanercept biosimilars. On the contrary, Lower Saxony, Westphalia-Lippe, Bavaria
and Northrhine showed high uptake for both infliximab and etanercept biosimilars (see Figure 5c).
Figure 5 shows a predominant location of low-uptake regions within the regions formerly
forming East Germany (Brandenburg, Mecklenburg Western Pomerania, Saxony, Saxony-Anhalt and
Thuringia). The statistical analysis conducted (see Section 4) indicated that biosimilar market shares
were significantly lower in former East Germany when compared to former West Germany. The
dichotomous variable East/West location has been considered a potential co-founder in this study. In
order to identify underlying predictor variables behind variable biosimilar uptake, multiple bivariate
regression models were conducted to study the statistical association between a number of determinants
of socio-economic welfare and regional biosimilar market shares. This is further detailed in Section 4.
None of the chosen socio-economic predictor variables were found to be significantly correlated to
regional biosimilar market shares.
2.3. The Role of Biosimilar Policies and Practices on Biosimilar Uptake: Interview Results
Physician associations regard biosimilars as a tool for economic prescribing and recommend
that physicians initiate eligible patients on biosimilars and switch from the reference product to the
biosimilar when possible. The view of physician associations has been generally consistent across
Germany, with some discrepancies on the importance given to maintaining the prescriber’s choice
over an argument of prescribing more economically. Relatively high price differences between the
biosimilar and the originator product after discounting were regarded by interviewees as a driver for
increased biosimilar use (see Table 2). Sickness fund representatives from the Saxony/Thuringia area
signaled that physicians may prefer to prescribe discounted originators over biosimilars when price
differences are small. This may explain the comparatively low biosimilar infliximab and etanercept
market shares in this area and, in general, in regions formerly forming East Germany. When asked for
reasons behind the lower biosimilar uptake in former East Germany regions, interviewees pointed to
the past reliance of eastern Germany physicians on the strategies applied by originator companies to
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increase customer fidelity. This may have created stronger historical bonds between physicians and
originator manufacturers that are still present today. It was also signaled that low biosimilar market
shares do not necessarily reflect inefficiency regarding economic prescribing, but reliance on alternative
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Table 2. Summary of factors identified to drive biosimilar use and facilitate biosimilar acceptance in
Germany. These factors have been identified through the qualitative analysis of interview data.
Drivers of Biosimilar Use Factors Facilitating Biosimilar Acceptance
Biosimilar prescription quotas:
-Efficient monitoring
-Presence of a sanctioning mechanism
Efficient communication between stakeholders
-Robust reporting capability of regional
physician associations
Greater cost-savings potential associated to biosimilars
Gainsharing contracts
Position statements/guidelines on the safety of switching
In contrast, physician and sickness fund representatives from Westphalia-Lippe supported the
prescription of biosimilars over originators, regardless of the real price difference realized after discount
agreements. Here, the strategic long-term perspective relied on viewing biosimilars as a tool to reduce
the increasing economic pressure that threatens the sustainability of the German Healthcare System.
Incentives for Increased Biosimilar Use
As stated by interviewees, certain policies/practices may affect the market penetration of biosimilars.
These can differ between regions and be associated with regional variations in biosimilar market shares.
Table 2 summarizes the identified drivers and facilitators for increased biosimilar use in Germany.
The establishment of biosimilar quotas was consistently identified as an important control
instrument to drive biosimilar use. Interviewees indicated that the success of quotas depends on the
effectiveness of the mechanisms put in place to monitor adherence to these quotas, as well as on the
presence of mechanisms to sanction non-adherence. Interviewees agreed on the importance of setting
out effective communication strategies to inform physicians about their accomplished prescribing
rates and to facilitate biosimilar acceptance. The effectiveness of these strategies would depend to
a certain extent on the robustness of the reporting capability of the regional physician associations.
Interviewees also indicated that the preferential use of biosimilars over originator products has been
driven by the organization of gainsharing contracts between groups of physicians and insurers. An
example is the BioLike initiative, launched by the insurer company Barmer GEK for gastroenterologists
and rheumatologists in different PA regions (e.g., Hamburg, Saarland, Saxony, Schleswig-Holstein,
Thuringia, Westphalia-Lippe). This initiative has led to an increased use of TNFα inhibitor biosimilars
and has allowed sharing the realized savings through biosimilar prescriptions between groups of
prescribers and the insurer companies [27]. One of the interviewed experts signaled the positive
experience of physicians with this initiative in Westphalia-Lippe.
Several German organizations, including the Drug Commission of the German Medical Association
(German: Arzneimittelkommission der deutschen Ärzteschaft (AkdÄ)), the Federal Association of
German Hospital Pharmacists (German: ADKA - Bundesverband Deutscher Krankenhausapotheker)
and the Paul Ehrlich Institute (German: Paul Ehrlich Institut (PEI)), have published favorable statements
on the safety of switching between a reference product and its corresponding biosimilars, as well
as between biosimilars [28–30]. Interviewees mentioned that the publication of these statements
may especially drive biosimilar acceptance in regions where biosimilar uptake has historically been
low (e.g., Baden-Württemberg). The views of stakeholders with respect to the benefits of allowing
the pharmacy-level automatic substitution of biologics (GSAV) are more divided. While physician
representatives have mostly expressed doubts about the added benefit of implementing this policy,
insurers have regarded it as an instrument for increased biosimilar use.
Interviewees participating in this study were also asked to identify factors primarily associated to
regional variations in biosimilar uptake. Both the differing regional-level implementation of biosimilar
quotas and the varying characteristics of procurement contracts appeared as important contributors.
Through a comparative analysis of regional agreements for biosimilar prescription quotas, the current
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study showed variability in the way the national recommendations have been implemented regionally
(see Table 3). Most regions have established binding biosimilar quotas. However, other regions
have defined prescribing targets to be interpreted as recommendations. While biosimilar quotas for
Westphalia-Lippe and Northrhine have historically been more ambitious than the national reference,
Baden-Württemberg has only established non-binding recommendations for specialists known to be
more familiar with TNFα inhibitor biosimilars (gastroenterologists and rheumatologists).
Table 3. Comparative analysis of regional quota agreements for TNFα inhibitors, based on information
available on the websites of the 17 German PA regions [31–47]. Quotas were set either generally for
biosimilars or more specifically for the therapeutic group or for each of the active substances within the
therapeutic group. Quotas may apply to all prescribers or to specific medical specialties.
Quota Agreements: Characteristics
Regions
Early Quota
Adoption:
(Before 2016)
Set
Unspecifically
for Biosimilars
Set for the
Category of TNFα
Inhibitors
Set for the
Active
Substance
Applied
Generally to
All Prescribers
Applied
Differently per
Specialty
Baden-Württemberg
√ √
Bavaria
√ √ √
Berlin
√ √
Brandenburg
√ √
Bremen
√ √
Hamburg
√ √
Hesse
√ √
Mecklenburg
Western
Pomerania:
(missing data)
Lower Saxony
√ √ √
Northrhine
√ √
Rhineland
Palatinate
√ √
Saarland
√ √
Saxony
√ √
Saxony-Anhalt
√ √
Schleswig
Holstein
√ √
Thuringia
√ √
Westphalia- Lippe
√ √ √
A certain flexibility has been allowed as well in the design and implementation of “open-house
rebate contracts” established at the insurer-manufacturer level. Interviewees indicated that this may
lead to intra- and inter-regional variability in biosimilar uptake. Interviewees in Westphalia-Lippe,
Saxony and Thuringia reported the possibility of sickness funds to follow more or less aggressive
strategies, depending on the magnitude of the pre-specified discount set as an entry requirement.
Contract participants may be asked to offer the maximum level of discount possible and entry
requirements may be set in a way that the differences in prices between the contract participants are
minimized. These strategies may discourage the participation of originator manufacturers, leading to
no discounts being negotiated for the originator. This limits the cost-savings potential that insurers
could have attained through lower net prices for originator products. Therefore, insurers may adopt
a less aggressive strategy where they ask for the maximum discount that the originator company
is willing to provide. This strategy, although it may meet the insurer’s cost-containment objectives,
results in lower than expected reductions of prices after biosimilar market entry.
3. Discussion
Across Europe, the level of market penetration for biosimilars has been described to be country-
and product-class-specific [7,48]. In Germany, we have found similar levels of market penetration for
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infliximab and etanercept biosimilars at the end of 2018. However, we had expected higher biosimilar
market penetration for etanercept due to the experience already gained by the market presence of
infliximab biosimilars. The lower than expected market penetration of etanercept biosimilars could
be partly explained by the different competition strategies followed by originator companies, which
were reported to be more aggressive in the case of etanercept. Interviewees also indicated that the
different administration routes for infliximab (intravenous) and etanercept (subcutaneous) may have
played a role. The switch from Enbrel® to etanercept biosimilars implies changes in the administration
device used by patients when self-administering the drug, while this is not the case for the switch from
Remicade® to infliximab biosimilars.
Previous biosimilar uptake studies in Sweden [17,18] and the current study for Germany have
shown that biosimilar market penetration is also region-specific and that there are wide regional
variations in biosimilar market shares for TNFα inhibitors [19]. Our study of biosimilar market shares
across the German regions showed common high and low uptake regions for infliximab and etanercept
biosimilars. The data on market shares for adalimumab biosimilars (up to 2020) [49] indicate that
regions where the uptake of infliximab and etanercept biosimilars has been high, also behaved as
early adopters for adalimumab biosimilars. Therefore, we presume that biosimilar incentive policies
applied regionally have had a consistent effect on the incorporation of biosimilars for the whole
class of TNFα inhibitors. This observation might not be applicable to other biologic therapies (e.g.,
filgrastim, follitropin α) for which biosimilar uptake patterns differ from the patterns described along
this study [49]. Several studies have investigated biosimilar policies implemented across Europe to
qualitatively assess their impact on biosimilar uptake [50,51]. Instead, the current study examined
regional variations in biosimilar uptake in order to derive practices/incentives influencing biosimilar
use. Studies published by Moorkens et al. [17,18] followed this approach and were among the first to
identify factors driving biosimilar use through quantitative analysis [52–54]. According to Moorkens
et al., the absolute/relative difference in discounted price between originator and biosimilars influence
decision-making regarding biosimilar use in Sweden [17]. We have not quantitatively evaluated price
effects on biosimilar uptake, as information on discounted/rebated prices was not available. However,
as described in the following section, we have been able to identify a set of incentive measures driving
the use of infliximab and etanercept biosimilars in Germany.
3.1. Incentives for Increased Biosimilar Use
This study described different approaches taken by the German regions to implement a
system of biosimilar prescription quotas. More active (e.g., Westphalia-Lippe) and less active (e.g.,
Baden-Württemberg) approaches were identified. Baden-Württemberg constituted an example of a
region where the implementation of biosimilar quotas was lenient and biosimilar uptake levels were
low. The role of lenient approaches on lack of adherence to biosimilar quotas has been commonly
reported [27,48]. The current study, however, indicates the importance of setting instruments to support
adherence with biosimilar quotas. Interviewees identified that these instruments are an effective
monitoring and sanctioning system and an effective communication strategy to bridge the objectives
of insurers, physician associations and individual prescribers. The capacity of regional physician
associations to actively communicate with physicians and to regularly report on achieved uptake levels
has been suggested as a factor driving biosimilar use in Westphalia-Lippe [55].
In Germany, the discounts realized through the establishment of “open-house rebate contracts”
are confidential. The real price difference between biosimilars and the respective originator product
is usually not known by prescribers. However, sickness funds are aware of the magnitude of the
discounted price difference between the originator and the biosimilar alternatives. Interviewees
indicated that this may define the commitment of insurers to incentivize biosimilar use over the use
of discounted originator products. Based on this, the investment in educational and other resources
needed to encourage biosimilar use may vary for the different sickness funds and for the different
regions. Gainsharing initiatives established across Germany are an example of the active involvement
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of sickness funds with the promotion of biosimilars. Some of these initiatives have opted to inform
participating physicians on net prices realized through discounting. It has been suggested that this
approach might increase the interest of physicians on the principles of cost-effective prescribing [27].
The publication of favorable statements on the safety of switching between reference products and
biosimilars is also an example of the active involvement of scientific expert committees. We hypothesize
that these committees operate as opinion leaders in Germany, having an influence on prescriber’s
decision-making regarding biosimilars.
Finally, the proposal to implement a policy for the automatic substitution of biologics at the
pharmacy level (GSAV) has elicited conflicting views among stakeholders in healthcare [19]. We
hypothesize that this measure may have a considerable impact on biosimilar uptake, potentially
equalizing differences in biosimilar market shares across Germany. Further research would be needed
to evaluate whether the implementation of this measure substantially changes the situation described
in this study.
3.2. Study Limitations
The analysis of market dynamics for the class of TNFα inhibitors was based on the availability of
data from ambulatory prescriptions covered by the SHI funds. The lack of information on prescriptions
issued by the PHI system or at the hospital level was not expected to affect the comprehensiveness of
the analysis, as most sales volume for TNFα inhibitors has been generated within the ambulatory care
sector and the SHI scheme is covering 87% of Germany’s population [8,56].
We conducted a regression analysis to assess the statistical relationship between several variables
chosen as predictors and the outcome variable (biosimilar market shares). We could only include
descriptors of socio-economic welfare and performance indicators for the different regional healthcare
systems as explanatory variables. Due to the lack of publicly available data, we could not study the
association between procurement contract conditions/real differences in discounted prices between
originators and biosimilars and regional biosimilar market shares. According to the view of the
experts interviewed for this study, we hypothesize that these factors may better explain regional-level
variability in biosimilar market shares. The availability of a limited number of observations (N = 16;
we combined the data from Northrhine and Westphalia-Lippe) also conditioned the analysis: only the
association between two predictor variables and market shares could be modelled simultaneously.
The qualitative analysis of interview data supplemented findings from the quantitative analysis
and identified regional predictors of biosimilar uptake that could not have been easily quantified
or proxied. However, it must be noted that these interviews were carried out only in nine of the 17
German PA regions. The lack of representation of every region is expected to have only a moderate
impact on the generalizability of the study findings, as the interviewed regions represent > 50% of the
sales volume for TNFα inhibitors in Germany.
3.3. Future Research
The current study provides an overview of market dynamics for the class of TNFα inhibitors in
Germany and especially evaluates the evolution in sales volume for all TNF α inhibitors after the market
entry of infliximab and etanercept biosimilars. To accurately evaluate the impact of biosimilar entry
within the class of TNFα inhibitors, we would have needed to study the evolution in costs per molecule
and per patient before and after the market launch of TNFα inhibitor biosimilars. This analysis could
not be conducted due to the lack of publicly available data, but it constitutes an interesting starting
point for future studies.
As part of this study, we have stressed the influence of biosimilar policies/practices for prescription
and budget control on biosimilar uptake. However, the implementation success for these policies has
varied across the German regions. It might be useful for future analyses to evaluate the cumulative
effect of implementing multiple incentive policies/practices and to see how this effect relates to observed
biosimilar market shares for the regions.
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4. Materials and Methods
The methodology chosen for this study is based on previous studies that investigated factors
influencing biosimilar uptake in Sweden [17,18]. We first conducted a literature review to describe
the main characteristics of the German market for TNFα inhibitors. For reasons of international
comparability, we refer to German-specific terminology identified through the literature search by
using the English equivalent term. A glossary table (see Table 4) with English terms used in this
manuscript and their German equivalent is provided below. Then, we examined dispensing data on
sales volume and biosimilar market shares for this drug class. In order to investigate potential factors
behind the variable regional uptake of infliximab and etanercept biosimilars, we relied on quantitative
and qualitative analyses conducted in parallel, as detailed in the following subsections.
Table 4. Glossary of English/German terms and abbreviations.
English Term German Term German Abbreviation
Drug Commission of the German Medical Association Arzneimittelkommission derdeutschen Ärzteschaft AkdÄ
Federal Association of Statutory Health Insurance Physicians Kassenärztliche Bundesvereinigung KBV
ADKA - Federal Association of German Hospital Pharmacists
ADKA - Arbeitsgemeinschaft
Deutscher Krankenhaus Apotheker
e.V.
-
Federal Joint Committee Gemeinsamer Bundesausschuss G-BA
Federal Ministry of Justice and Consumer Protection Bundesministerium der Justiz und fürVerbraucherschutz BMJV
ABDA - Federal Union of German Associations of Pharmacists ABDA - BundesvereinigungDeutscher Apothekerverbände e.V. -
German Institute for Drug Use Evaluation Deutsches Arzneiprüfungsinstitut e.V. DAPI
German law for more safety in the supply of pharmaceuticals Gesetz für mehr Sicherheit in derArzneimittelversorgung GSAV
German federal states Bundesländer -
German Regional Associations of Statutory Health Insurance
Accredited Physicians (also referred to in text as PA regions):
To be noted:
-This paper makes a distinction between the 16 German federal
states and the 17 PA regions. Although Germany is divided
into 16 federal states, the areas Northrhine and
Westphalia-Lippe within the state Northrhine-Westphalia are
represented by two independent PA regions.
-Dispensing data have been provided/analysed per PA region
and the univariate regression study has been conducted with
data at the state level. This was due to limitations in data
availability for the univariate regression analyses.
-When referring to regions formerly forming East Germany, we
include Brandenburg, Mecklenburg Western Pomerania,
Saxony, Saxony-Anhalt and Thuringia, but not Berlin. This is
because we do not have sub regional data to analyze uptake
differences between areas formerly forming East and West
Berlin.
Kassenärztliche Vereinigungen KV
National Association of Statutory Health Insurance Funds GesetzlicheKrankenversicherung-Spitzenverband GKV-SV
National advisory agreement on spending targets:
(also referred to in text as national-level agreements on
prescription targets)
Bundesrahmenvorgaben für die
Arzneimittelvereinbarungen -
“Open-house rebate” contracts Open-House-Rabattverträge -
Private Health Insurance (abbreviated in text as PHI) Private Krankenversicherung PKV
Regional agreements on prescribing spending targets, supply
and economy targets (also referred to in text as regional-level
contracts to establish prescribing quotas)
Arzneimittelvereinbarungen -
Sickness Funds (also referred to in text as insurer
organizations or insurers) Krankenkassen -
Social Code Book V (Statutory Health Insurance) Sozialgesetzbuch V (GesetzlicheKrankenversicherung) SGB V
Statutory Health Insurance (abbreviated in text as SHI) Gesetzliche Krankenversicherung GKV
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4.1. Literature Review
The main characteristics of the German healthcare system in dealing with biologics, including
biosimilars, were extracted from a literature review. PubMed, Embase and Scopus were searched up to
December 2019 to yield information on combined searches including the terms: policies, practices,
measures, biosimilars and Germany. Studies in English and German were accepted. The website of
the Federal Ministry of Justice and Consumer Protection (German: Bundesministerium der Justiz
und für Verbraucherschutz (BMJV)) was accessed to retrieve relevant articles from the German Social
Code Book (SGB) V [57]. Additionally, the websites of the KBV [58], the different KVs [31–47], and the
GKV-SV were consulted [59].
4.2. Analysis of Dispensing Data for TNFα Inhibitors
Regional data on sales volume and uptake of TNFα inhibitor originators and biosimilars were
provided by the database of the German Institute for Drug Use Evaluation (German: Deutsches
Arzneiprüfungsinstitut e.V. (DAPI)). This database contains anonymous claims data of drugs prescribed
and subsequently dispensed by community pharmacies at the expense of the SHI Funds. Nearly 87%
of Germany’s population is insured by the SHI system [8,56]. The DAPI database covers all claims data
from a representative sample of more than 80% of the community pharmacies throughout all regions.
Dispensing data were linked to the database of the ABDA – Federal Union of German Associations of
Pharmacists (German: ABDA—Bundesvereinigung Deutscher Apothekerverbände e.V.) containing
information about the (brand) name, composition, active ingredient, strength, package size, dosage
form, and route of administration of German medicinal products [60]. Defined daily doses (DDDs) [61]
were calculated from dispensing data and extrapolated by regional factors to 100% of all community
pharmacies, and thus 100% of the SHI insured population.
For this analysis, drug use data were examined from the first quarter (Q1) of 2010 to the last quarter
(Q4) of 2018. The study of the evolution of sales volume (DDDs) for all marketed TNFα inhibitors
allowed us to visualize the effect of the market entry of infliximab and etanercept biosimilars. In
addition, shifts in drug utilization trends across the class of TNFα inhibitors were described following
biosimilar incorporation, as well as after the market entry of the innovator therapies Cimzia® and
Simponi®. Biosimilar market shares were calculated from volume data (DDDs) and represented the
volume of biosimilars over the volume of biosimilars plus the respective originator product. The
evolution of biosimilar market shares for infliximab and etanercept was studied at the national level
and across the 17 PA regions from the quarter in which the biosimilar entered the market (Q1 2015 for
infliximab; Q1 2016 for etanercept) to the last quarter of 2018. The regional analysis of market shares
allowed the identification of high- and low-biosimilar uptake regions. Uptake was considered to be
high in regions where biosimilar market shares were ≥69% for infliximab and ≥63% for etanercept,
and low in regions where market shares were ≤51% for infliximab and ≤48% for etanercept. (These
thresholds correspond to the lower and upper third of the maximum difference in market shares
observed for Q4 2018).
The predominant location of low-uptake regions within the former East Germany, i.e., Brandenburg,
Mecklenburg Western Pomerania, Saxony, Saxony-Anhalt and Thuringia, led us to evaluate the
statistical relationship between regional biosimilar market shares (dependent variable; N = 16) and
the East/West location of the regions at a level of significance of 0.05. This univariate regression
analysis was conducted with SPSS (IBM SPSS Statistics 26). Two regression models, one accounting for
infliximab data and another for etanercept were built and used as a baseline for a more exhaustive
statistical analysis. As the East/West location of the regions was considered to be a co-founding
variable, the objective of conducting a more exhaustive analysis was to identify underlying predictor
variables (socio-economic factors) behind variable biosimilar uptake. We built various bivariate
regression models to examine the statistical relationship between biosimilar market shares and a
set of predictors describing: (1) the variable level of socio-economic welfare across the 16 German
federal states (e.g., gross domestic product (GDP) per capita, human development index) and (2) the
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performance of the different regional healthcare systems (e.g., number of healthcare workers employed
per 1000 inhabitants, total healthcare expenditure and healthcare expenditure calculated as a share of
GDP) [62]. Furthermore, we studied the correlation between regional biosimilar market shares for
infliximab and etanercept to evaluate whether biosimilar uptake patterns were similar within the class
of TNFα inhibitors.
4.3. Interviews
A total of ten semi-structured interviews (12 participants) were organized from October 2018 to
February 2020 with a view to gain insight into factors potentially influencing biosimilar uptake. The
conduction of interviews allowed us to complement the findings from the quantitative analysis and to
investigate determinants of biosimilar uptake that could not have be evaluated quantitatively.
A selective sampling methodology was followed to achieve representation from physician
associations and health insurance companies operating at the national and regional level. The
interviewed representatives from these two stakeholder groups have been involved in decision-making
regarding drug budget and prescription control activities and have expertise in the field of biosimilars.
Participation from representatives in Baden-Württemberg, Bremen, Hamburg, Mecklenburg Western
Pomerania, Lower Saxony, Saxony, Schleswig-Holstein, Thuringia and Westphalia-Lippe was achieved.
For data collection, an interview guide was drafted, validated and approved (August 2018) by
the UZ/KU Leuven ethics committee (reference number: MP006423). The interview guide followed
the structure of a guide previously developed by the department to study regional management of
biosimilars in Sweden [17,18]. The topics were adapted for Germany through a literature search
conducted as part of a master’s thesis [63]. Interview questions were organized into questions on
dispensing data for TNFα inhibitors and questions on national and regional-level biosimilar policies.
All interviewees received an email with an attached informed consent form and were asked for
permission to record the interviews. All interviews were conducted in English via telephone calls.
The recorded interviews were transcribed ad verbatim and processed using the software QSS NVivo
12. For content analysis, we built a thematic framework based on previous knowledge and findings
emerging from the interviews. The results of the qualitative study were shared with the contacted
interviewees for a validation exercise.
5. Conclusions
Variation in market penetration of TNFα inhibitor biosimilars between German regions depends
on a complex interplay of multiple factors.
Experts interviewed for this study have highlighted the influence of prescription and budget
control activities (organized at the regional and insurer level) on the variable uptake of infliximab
and etanercept biosimilars across Germany. The use of biosimilars has been found to depend on:
the regional-level implementation of biosimilar quotas, the presence of an effective monitoring and
sanctioning system to regulate adherence to biosimilar quotas, the effectiveness of the communication
between regional physician associations and individual prescribers, the different conditions for
discount contracts established at the insurer-manufacturer level and the organization of initiatives for
gainsharing. The allowance of pharmacy-level automatic substitution for biologics is expected to play
a decisive role in the evolution of biosimilar consumption patterns across Germany.
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